STOCK TITAN

United Therapeutics (UTHR) CFO sells 10K shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of Common Stock at a price of $117.76 per share and, on the same date, sold 10,000 shares of Common Stock in a series of open-market transactions.

The reported sales occurred at weighted average prices ranging from approximately $561.48 to $571.48 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, Edgemond directly holds 18,876 shares of Common Stock and 50,000 stock options.

Positive

  • None.

Negative

  • None.
Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.66M)
Type Security Shares Price Value
Exercise Stock Option 10,000 $0.00 --
Exercise Common Stock 10,000 $117.76 $1.18M
Sale Common Stock 320 $561.4823 $180K
Sale Common Stock 1,961 $562.7676 $1.10M
Sale Common Stock 1,675 $563.8743 $944K
Sale Common Stock 1,208 $564.8205 $682K
Sale Common Stock 893 $565.9956 $505K
Sale Common Stock 934 $566.8663 $529K
Sale Common Stock 1,605 $567.9143 $912K
Sale Common Stock 844 $568.9008 $480K
Sale Common Stock 332 $570.4955 $189K
Sale Common Stock 228 $571.4811 $130K
Holdings After Transaction: Stock Option — 50,000 shares (Direct, null); Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
  1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $570.01 to $570.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $571.06 to $571.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $561.09 to $562.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $562.38 to $563.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $563.39 to $564.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $564.40 to $565.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $565.42 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $566.46 to $567.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $567.46 to $568.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $568.55 to $569.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 10,000 shares Total Common Stock sold across 10 open-market transactions
Option exercise size 10,000 shares Common Stock acquired via stock option exercise
Option exercise price $117.76 per share Exercise price for 10,000 stock options
Sale price (example) $571.4811 per share Weighted average price for a 228-share sale lot
Shares held after 18,876 shares Common Stock directly owned following transactions
Options remaining 50,000 options Stock options outstanding after the reported exercise
Net share activity -10,000 shares Net buy/sell direction from transaction summary
Rule 10b5-1 trading plan financial
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/28/2026M(1)10,000A$117.7628,876D
Common Stock05/28/2026S(1)320D$561.4823(2)28,556D
Common Stock05/28/2026S(1)1,961D$562.7676(3)26,595D
Common Stock05/28/2026S(1)1,675D$563.8743(4)24,920D
Common Stock05/28/2026S(1)1,208D$564.8205(5)23,712D
Common Stock05/28/2026S(1)893D$565.9956(6)22,819D
Common Stock05/28/2026S(1)934D$566.8663(7)21,885D
Common Stock05/28/2026S(1)1,605D$567.9143(8)20,280D
Common Stock05/28/2026S(1)844D$568.9008(9)19,436D
Common Stock05/28/2026S(1)332D$570.4955(10)19,104D
Common Stock05/28/2026S(1)228D$571.4811(11)18,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$117.7605/28/2026M(1)10,00003/15/202303/15/2027Common Stock10,000$0.0050,000D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $561.09 to $562.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $562.38 to $563.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $563.39 to $564.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $564.40 to $565.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $565.42 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $566.46 to $567.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $567.46 to $568.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $568.55 to $569.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $570.01 to $570.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $571.06 to $571.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did United Therapeutics (UTHR) CFO James Edgemond do in this Form 4 filing?

CFO James Edgemond exercised stock options for 10,000 United Therapeutics shares and sold 10,000 shares in open-market transactions. These actions were reported as part of a routine Form 4 insider trading disclosure with detailed share and price information.

How many United Therapeutics (UTHR) shares did the CFO sell and at what prices?

James Edgemond sold 10,000 United Therapeutics Common Stock shares across multiple trades. The reported weighted average sale prices ranged roughly between $561.48 and $571.48 per share, with separate transactions disclosed at specific weighted average prices for each trade group.

Did the United Therapeutics (UTHR) CFO exercise stock options in this transaction?

Yes, the CFO exercised stock options covering 10,000 United Therapeutics Common Stock shares at an exercise price of $117.76 per share. This option exercise was followed by open-market sales of an equal number of underlying common shares on the same date.

How many United Therapeutics (UTHR) shares does the CFO hold after these transactions?

After the reported option exercise and related share sales, CFO James Edgemond directly holds 18,876 shares of United Therapeutics Common Stock. He also holds 50,000 stock options, providing additional potential equity exposure beyond his current common share position.

Were the United Therapeutics (UTHR) CFO’s trades made under a Rule 10b5-1 plan?

Yes, the filing states that the stock option exercise and subsequent sale of shares were made pursuant to a Rule 10b5-1 trading plan. That plan was entered into by the reporting person on October 31, 2025, indicating the transactions were pre-arranged rather than ad hoc.

What is the net effect of these insider transactions on the CFO’s United Therapeutics (UTHR) position?

The CFO exercised 10,000 options and sold 10,000 common shares, with Form 4 summary data showing net sell activity of 10,000 shares. He still directly holds 18,876 common shares and 50,000 stock options, maintaining a significant ongoing equity interest.